As Professor in Directed Evolution and Antibody Technology Johan Rockberg heads a research group at KTH Royal Institute of Technology, Stockholm. His research team has a strong method development focus, directed at both discovery and bioprocess development of next generation biologics, including gene therapy. To this end, directed evolution and systems biology are tools used for improvement of both compound and producer cell lines. He is the director of GeneNova, for the development of next generation bioproduction platforms for virus-based gene therapy. Since 2019, Prof. Rockberg is an elected member of the Swedish Young Academy. He has been holding industry positions as Director Biosynergy at Alligator Bioscience AB, Lund Sweden, as CSO of Atlas Therapeutics AB, Stockholm Sweden and is a co-founder of of several cutting edge companies focusing on cancer immunotherapy.